Organization · Venture Capital
EMBL Ventures
EMBL Ventures is a Heidelberg-based early-stage venture capital firm focused on life sciences, investing across Europe in companies developing innovative therapeutic modalities, pharmaceuticals, and medical technologies.
Overview
What EMBL Ventures does
What EMBL Ventures is
EMBL Ventures is a Heidelberg-based early-stage venture capital firm focused on life sciences, investing across Europe in companies developing innovative therapeutic modalities, pharmaceuticals, and medical technologies.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2001
- Approximate age
- About 25 years
- Structured capabilities
- Funder
- Last reviewed
- April 9, 2026
Official channels
Find EMBL Ventures elsewhere
Open the official website or a supported primary organization account.
Capability profile
EMBL Ventures as a funder
Investment thesis
EMBL Ventures exclusively focuses on life sciences, targeting companies that develop new therapeutic modalities, pharmaceuticals, enabling technology platforms, diagnostics, and medical devices. The firm leverages its connection with EMBL to access a rich scientific network and proprietary research.
Focus narrative
EMBL Ventures invests in life science technologies across Europe, focusing on companies that leverage significant scientific advancements. The organization seeks to build companies that create new therapeutic modalities, pharmaceuticals, enabling technology platforms, and innovations in diagnostics and medical devices.
Value beyond capital
EMBL Ventures provides portfolio companies with access to a vast scientific network and proprietary research through its affiliation with EMBL. The team brings extensive experience in company building, M&A, licensing agreements, and IPOs, offering strategic guidance and support.
Terms and economics
- Typical check
- $3,200,000–$5,500,000
Focus and fit
- Stages
- Seed · Series A · Series B
- Regions
- Europe
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded notable exits
- ViraTherapeutics and Luxendo
Portfolio context
Notable portfolio companies include ViraTherapeutics, which was acquired by Boehringer Ingelheim for approximately USD 245M, and Luxendo, co-led in Series A and later acquired by Bruker in 2018. Additional portfolio companies can be found through EMBLEM's portfolio page.
Common questions
What to know about EMBL Ventures
Upseed classifies EMBL Ventures under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 9, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.